Literature DB >> 10464328

Goodpasture disease. Characterization of a single conformational epitope as the target of pathogenic autoantibodies.

T Hellmark1, H Burkhardt, J Wieslander.   

Abstract

Goodpasture disease is a prototype autoimmune disease characterized by the formation of autoantibodies against the heterotrimeric basement membrane collagen type IV, which causes a rapidly progressive glomerulonephritis. The pathogenic antibody response is directed to the non-collagenous (NC1) domain of the alpha3 chain of type IV collagen (alpha3(IV)NC1), but not to the homologous region of the alpha1(IV)NC1. To identify the conformation-dependent immunodominant epitope on the alpha3(IV)NC1, a variety of recombinant NC1 domains were constructed by replacing single residues of alpha3(IV) with the corresponding amino acids from the nonreactive alpha1(IV) chain. Replacement mutations were identified that completely destroyed the Goodpasture epitope in the alpha3(IV) chain. Based on the identification of these critical positions, the epitope was finally reconstructed within the frame of the alpha1(IV) chain. The substitution of nine discontinuous positions in the alpha1(IV)NC1 with amino acid residues from the alpha3 chain resulted in a recombinant construct that was recognized by all patients' sera (n = 20) but by none of the sera from healthy controls (n = 10). This provides, for the first time, the molecular characterization of a single immunodominant conformational epitope recognized by pathogenic autoantibodies in a human autoimmune disease, representing the basis for the development of new epitope-specific strategies in the treatment of Goodpasture disease.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10464328     DOI: 10.1074/jbc.274.36.25862

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  22 in total

1.  Murine membranous nephropathy: immunization with α3(IV) collagen fragment induces subepithelial immune complexes and FcγR-independent nephrotic syndrome.

Authors:  Jun-Jun Zhang; Mahdi Malekpour; Wentian Luo; Linna Ge; Florina Olaru; Xu-Ping Wang; Maimouna Bah; Yoshikazu Sado; Laurence Heidet; Sandra Kleinau; Agnes B Fogo; Dorin-Bogdan Borza
Journal:  J Immunol       Date:  2012-02-27       Impact factor: 5.422

2.  Molecular architecture of the Goodpasture autoantigen in anti-GBM nephritis.

Authors:  Vadim Pedchenko; Olga Bondar; Agnes B Fogo; Roberto Vanacore; Paul Voziyan; A Richard Kitching; Jörgen Wieslander; Clifford Kashtan; Dorin-Bogdan Borza; Eric G Neilson; Curtis B Wilson; Billy G Hudson
Journal:  N Engl J Med       Date:  2010-07-22       Impact factor: 91.245

3.  Identification of noncollagenous sites encoding specific interactions and quaternary assembly of alpha 3 alpha 4 alpha 5(IV) collagen: implications for Alport gene therapy.

Authors:  Jeong Suk Kang; Selene Colon; Thomas Hellmark; Yoshikazu Sado; Billy G Hudson; Dorin-Bogdan Borza
Journal:  J Biol Chem       Date:  2008-10-16       Impact factor: 5.157

Review 4.  Novel therapeutic approaches for progressive renal disorders by targeting glomerular component mesangial and endothelial cells.

Authors:  Yohei Maeshima
Journal:  Clin Exp Nephrol       Date:  2005-12       Impact factor: 2.801

Review 5.  Goodpasture's disease: molecular architecture of the autoantigen provides clues to etiology and pathogenesis.

Authors:  Vadim Pedchenko; Roberto Vanacore; Billy Hudson
Journal:  Curr Opin Nephrol Hypertens       Date:  2011-05       Impact factor: 2.894

Review 6.  Autoantigen complementarity: a new theory implicating complementary proteins as initiators of autoimmune disease.

Authors:  William F Pendergraft; Barrak M Pressler; J Charles Jennette; Ronald J Falk; Gloria A Preston
Journal:  J Mol Med (Berl)       Date:  2004-12-11       Impact factor: 4.599

7.  Zebrafish to humans: evolution of the alpha3-chain of type IV collagen and emergence of the autoimmune epitopes associated with Goodpasture syndrome.

Authors:  Brian A MacDonald; Malin Sund; Marianne A Grant; Kathleen L Pfaff; Kathryn Holthaus; Leonard I Zon; Raghu Kalluri
Journal:  Blood       Date:  2005-10-27       Impact factor: 22.113

Review 8.  [Rapidly progressive glomerulonephritis:classification, pathogenesis and clinical management].

Authors:  R Birck; F J Van Der Woude
Journal:  Internist (Berl)       Date:  2003-09       Impact factor: 0.743

9.  Epitope mapping of anti-PR3 antibodies using chimeric human/mouse PR3 recombinant proteins.

Authors:  D Selga; M Segelmark; J Wieslander; L Gunnarsson; T Hellmark
Journal:  Clin Exp Immunol       Date:  2004-01       Impact factor: 4.330

10.  Novel targets for immunotherapy in glomerulonephritis.

Authors:  Mary H Foster
Journal:  Biologics       Date:  2008-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.